Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00074009
First received: December 10, 2003
Last updated: February 11, 2012
Last verified: December 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Publications: